Italian angels, incubators and venture capitalists keep investing in the domestic and foreign market showing a keen interest in fintech, and biotech, as well as in the energy sector.
Italy’s Metis Precision Medicine raised o.45 million of euros from Club degli Investitori, a Piedmont-based network of business angels that Giancarlo Rocchietti is chairing (see here a previous post by BeBeez). Metis aims to develop an anti-cancer drug. With the new investment round, the company may start the pre-clinical trial stage and record its intellectual property. Businessmen Giorgio Barberis and Mauro Ferrari allowed MPM to liaise with Club degli Investitori.
Italy’s venture capital firm Principia Health, invested in the CheckMab, a spin-off Milan University togheter with Istituto Nazionale di Genetica Molecolare (INGM) and researchers Sergio Abrignani and Massimiliano Pagani (see here a previous post by BeBeez). This injection of capital will allow CheckMab to develop the pre-clinic and pre-industrial stage of anticancer treatment. After such 11th investment, Principia Health allocated more than 60% of its resources worth 206 million of euros.
Tego Oil Llc, a Kansas based oil company, raised 0.6 million of dollars from Club Investitori Italia, a financial firm of which Federico Tralli is the chairman. Bill Bollander, a member of CII’s Strategic Team, scouted the asset (see here a previous post by BeBeez). This is the first of the four deals that CII aims to close by the end of 2018. Brixia based investors, entrepreneurs and managers founded CII for investinf in structured companies in Italy and abroad that have a reliable management and cash flow.
Silvano Spinelli is the new venture partner of Sofinnova Partners, the European firm with a focus on biotech (see here a previous post by BeBeez). Spinelli will still chair BiovelocITA, the Italian accelerator with a focus on red-biotech that he co-founded with Gabriella Camboni and Sofinnova Partners that since 2015 raised 15 million of euros from founders and further investors. In 1999 Sofinnova Partners invested in Novuspharma, an oncology company that Spinelli launched and listed on Nuovo Mercato in 2000 after having raised more than 160 million of euros, and that Cell Therapeutics acquired in 2003.
